1
|
Taniguchi K, Goto K, Yabushita H, Yamasaki R, Ichimura K. Transcriptional repressor GATA binding 1 (TRPS1) immunoexpression in normal skin tissues and various cutaneous tumors. J Cutan Pathol 2023; 50:1006-1013. [PMID: 37649299 DOI: 10.1111/cup.14523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 08/14/2023] [Accepted: 08/21/2023] [Indexed: 09/01/2023]
Abstract
BACKGROUND Transcriptional repressor GATA binding 1 (TRPS1) is a transcription factor recently shown to play a role in the development of breast and liver cancer. Here, we evaluate TRPS1 immunoexpression in normal skin tissues and various cutaneous tumors. METHODS TRPS1 immunohistochemistry was performed in 109 cases of primary cutaneous tumors and 19 cases of metastatic carcinomas. TRPS1 expression was also evaluated in the normal skin tissues. RESULTS The normal epidermis was TRPS1-. In contrast, the eccrine apparatus, epithelial compartment of the hair follicles, hair papilla, sebaceous glands, and anogenital mammary-like glands were TRPS1+. In primary cutaneous tumors, TRPS1 positivity varied in poroma (2/3), nodular hidradenoma (4/5), spiradenoma (4/4), cutaneous mixed tumor (5/5), trichilemmal cyst (7/8), proliferating trichilemmal tumor (1/3), pilomatricoma (9/9), sebaceoma (2/5), extramammary Paget disease (13/13), sebaceous carcinoma (2/2), actinic keratosis (3/10), Bowen disease (7/12), and squamous cell carcinoma (1/5) cases. All cases of seborrheic keratosis, basal cell carcinoma, Merkel cell carcinoma, and malignant melanoma were TRPS1-. All metastatic breast carcinoma cases (8/8) were highly positive for TRPS1, while all but one of the other metastatic tumor cases were TRPS1-. CONCLUSIONS TRPS1 immunoexpression was observed in several skin appendages and cutaneous tumors.
Collapse
Affiliation(s)
- Kohei Taniguchi
- Department of Pathology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Keisuke Goto
- Department of Pathology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
- Department of Pathology, Itabashi Central Clinical Laboratory, Tokyo, Japan
- Department of Diagnostic Pathology, Tokyo Medical University Hospital, Tokyo, Japan
- Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan
- Department of Diagnostic Pathology, Chutoen General Medical Center, Kakegawa, Japan
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan
- Department of Diagnostic Pathology, Osaka National Hospital, Osaka, Japan
- Department of Dermatology, Hyogo Cancer Center, Akashi, Japan
- Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan
| | - Hiroki Yabushita
- Department of Pathology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Rie Yamasaki
- Department of Pathology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Koichi Ichimura
- Department of Pathology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| |
Collapse
|
2
|
Bogiatzi S, Estenaga A, Louveau B, Osio A, Deschamps L, Mourah S, Poirot B, Lehmann-Che J, Cribier B, Battistella M. Microsecretory adenocarcinoma of the skin, a novel type of sweat gland carcinoma: Report of three additional cases. J Cutan Pathol 2023; 50:897-902. [PMID: 36790018 DOI: 10.1111/cup.14408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 02/07/2023] [Accepted: 02/08/2023] [Indexed: 02/16/2023]
Abstract
Microsecretory adenocarcinoma (MSA) is a newly described salivary gland tumor harboring a characteristic balanced chromosomal translocation resulting in MEF2C::SS18 gene fusion. Six primary cutaneous MSA cases have been recently described. We report three additional cases confirming the relevance of this recently identified entity of primary cutaneous adnexal tumor. Three patients aged 53-, 64- and 78-year-old were retrospectively diagnosed with MSA of the skin (MSAS) as consultation cases of the CARADERM (CAncers RAres DERMatologiques) national network. The clinical presentation was an indolent nodule on the upper extremities. There was no history of salivary gland tumor. Histopathologically, the tumors presented as dermal nodular proliferation with slightly infiltrative borders, composed of cribriform and microcystic structures with abundant myxoid intraluminal secretion embedded in a fibromyxoid stroma. They diffusely expressed cytokeratin 8 and SOX10, focally p63 and heterogeneously smooth muscle actin. All tumors harbored the MEF2C::SS18 gene fusion. A complete surgical excision was performed. No local recurrence or distant metastases were observed so far (follow-up: 17, 38, and 45 months). MSAS is the cutaneous homologue of MSA of the salivary gland, a low-grade adnexal neoplasm whose prognosis seems to be excellent once the complete removal of the tumor is assured.
Collapse
Affiliation(s)
- Sofia Bogiatzi
- Pathology Department, Saint-Louis Hospital, Paris, France
| | | | - Baptiste Louveau
- Solid Tumor Genomics Department, Saint-Louis Hospital, Paris, France
| | - Amélie Osio
- Pathology Department, Saint-Louis Hospital, Paris, France
| | | | - Samia Mourah
- Solid Tumor Genomics Department, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Paris, France
| | - Brigitte Poirot
- Solid Tumor Genomics Department, Saint-Louis Hospital, Paris, France
| | - Jacqueline Lehmann-Che
- Solid Tumor Genomics Department, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Paris, France
| | - Bernard Cribier
- Dermatopathology Unit, Clinique Dermatologique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Maxime Battistella
- Pathology Department, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Paris, France
| |
Collapse
|
3
|
Panse G. Microsecretory adenocarcinoma: Cutaneous counterpart of a newly described salivary gland tumor with recurrent MEF2C::SS18 fusion. J Cutan Pathol 2023; 50:188-190. [PMID: 36308392 DOI: 10.1111/cup.14349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 09/26/2022] [Accepted: 10/15/2022] [Indexed: 01/24/2023]
Abstract
Microsecretory adenocarcinoma (MSA) is a distinctive low-grade salivary gland tumor with a novel MEF2C::SS18 fusion. Although MSA most commonly occurs in the oral cavity, cases of MSA involving skin have been described recently. Histopathologically, MSA is characterized by microcystic tubules with basophilic luminal secretions, a fibromyxoid stroma and cells with eosinophilic or clear cytoplasm, and a unique immunohistochemical profile (S100+, SOX10+, p63+, and p40-). Cutaneous MSA may rarely demonstrate high-grade features. Follow-up studies have shown MSA to be an indolent tumor, without local recurrence or metastasis after complete surgical excision in the vast majority of cases. It is important to recognize the histopathological features of this unique tumor with a novel MEF2C::SS18 fusion that may occur in skin and to utilize appropriate molecular studies for accurate diagnosis.
Collapse
Affiliation(s)
- Gauri Panse
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.,Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA
| |
Collapse
|
4
|
Gibbs DC, Yeung H, Blalock TW. Incidence and trends of cutaneous adnexal tumors in the United States in 2000-2018: A population-based study. J Am Acad Dermatol 2023; 88:226-228. [PMID: 35525505 PMCID: PMC10263389 DOI: 10.1016/j.jaad.2022.04.052] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 04/21/2022] [Accepted: 04/25/2022] [Indexed: 10/18/2022]
Affiliation(s)
- David C Gibbs
- Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
| | - Howa Yeung
- Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia; Winship Cancer Institute of Emory University School of Medicine, Atlanta, Georgia; Atlanta VA Health Care System, Decatur, Georgia
| | - Travis W Blalock
- Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia; Winship Cancer Institute of Emory University School of Medicine, Atlanta, Georgia; Atlanta VA Health Care System, Decatur, Georgia.
| |
Collapse
|
5
|
Affiliation(s)
- Julia Stiegler
- Division of Dermatologic Surgery, University of Rochester Medical Center, Rochester, New York
| | - Sean Mogan
- Ocusight Eye Care Center, Rochester, New York.,Department of Ophthalmology, University of Rochester Medical Center, Rochester, New York
| | - Tatsiana Pukhalskaya
- Department of Pathology, University of Rochester Medical Center, Rochester, New York
| | - Brendon Verhave
- Dermatology Clinical Trials Unit, University of Rochester Medical Center, Rochester, New York
| | - Sherrif F Ibrahim
- Division of Dermatologic Surgery, University of Rochester Medical Center, Rochester, New York
| |
Collapse
|
6
|
Evangelista MTP, North JP. MYB, CD117 and SOX-10 expression in cutaneous adnexal tumors. J Cutan Pathol 2017; 44:444-450. [PMID: 28098399 DOI: 10.1111/cup.12904] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Revised: 01/12/2017] [Accepted: 01/13/2017] [Indexed: 01/01/2023]
Abstract
BACKGROUND Elevated MYB expression has been documented in adenoid cystic carcinoma (ACC), cylindroma, and spiradenoma, but the specificity of this finding is unknown. CD117 and SOX-10 expression also occurs in some cutaneous adnexal tumors. This study assesses MYB, CD117 and SOX-10 expression in cutaneous adnexal tumors. METHODS Retrospective analysis of 184 benign adnexal tumors (140 eccrine/apocrine, 40 follicular and 10 sebaceous), and 30 malignant adnexal tumors was performed with MYB, SOX-10 and CD117 immunostaining. RESULTS In the benign adnexal tumors, 16% (23/140) significantly expressed MYB. MYB expression was limited to cylindromas and to a lesser extent, spiradenomas in the benign cohort. Elevated MYB expression was detected in mucinous carcinoma, endocrine mucin-producing sweat gland carcinoma and 1 and 4 cases of extramammary Paget's disease (EMPD) in the malignant cohort. CD117 and SOX-10 had similar overall positivity rates in benign apocrine and eccrine tumors (45% and 68% respectively), and were generally negative in other benign and malignant adnexal tumors. CONCLUSION Expression of MYB appears limited to a small number of cutaneous adnexal tumors, including cylindromas, spiradenomas, ACCs, mucinous carcinoma, endocrine mucin-producing sweat gland carcinoma and some cases of EMPD.
Collapse
Affiliation(s)
| | - Jeffrey P North
- Departments of Dermatology and Pathology, University of California, San Francisco, California
| |
Collapse
|
7
|
Jinnah AH, Emory CL, Mai NH, Bergman S, Salih ZT. Hidradenocarcinoma presenting as soft tissue mass: Case report with cytomorphologic description, histologic correlation, and differential diagnosis. Diagn Cytopathol 2016; 44:438-41. [PMID: 26876052 DOI: 10.1002/dc.23449] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Revised: 12/21/2015] [Accepted: 01/06/2016] [Indexed: 11/11/2022]
Abstract
Hidradenocarcinoma (HAC) is a rare adenexal tumor with a propensity for the head and neck region and extremities. We report a case of hidradenocarcinnoma in a 56-year-old woman with a mass on her right palm sampled by fine-needle aspiration and later confirmed on histological examination. Fine-needle aspiration cytology revealed a dual population of cells including polyhedral eosinophilic cells and glycogen containing cells with pale/clear cytoplasm. The nuclei were pleomorphic with prominent nucleoli. Occassional papillary structures were identified on the cell block material. A series of immunohistochemical stains were performed and an adnexal neoplasm was suggested. The mass was resected. On histologic sections, infiltration into the adjacent soft tissue was identified. After an additional series of immunohistochemical stains, the diagnosis was confirmed as a HAC. Herein, we present our findings and discuss the differential diagnoses.
Collapse
Affiliation(s)
- Alexander H Jinnah
- Department of Orthopaedic Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Cynthia L Emory
- Department of Orthopaedic Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Nicholas H Mai
- Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Simon Bergman
- Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Ziyan T Salih
- Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| |
Collapse
|